Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig's disease, presents a significant global health challenge. The 2019 global estimates show approximately 39,081 deaths attributed to motor neuron diseases, including ALS, highlighting the urgency for advancements. With an estimated 30,000 Americans and 35,000 Europeans living with ALS, the need for effective solutions is clear. The progression is rapid, often leading to respiratory failure within 3-5 years of diagnosis. We know that 90-95% of ALS cases are sporadic (sALS), while 5-10% are familial (fALS).

𝗧𝗵𝗲 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝘂𝗻𝗺𝗲𝘁 𝗻𝗲𝗲𝗱𝘀 𝗿𝗲𝗺𝗮𝗶𝗻: disease-modifying therapies, effective first-line treatments, and biomarkers for early diagnosis.
𝘞𝘩𝘪𝘭𝘦 𝘵𝘩𝘦 𝘱𝘪𝘱𝘦𝘭𝘪𝘯𝘦 𝘪𝘴 𝘱𝘳𝘰𝘮𝘪𝘴𝘪𝘯𝘨, 𝘤𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘷𝘦 𝘦𝘧𝘧𝘰𝘳𝘵𝘴 𝘢𝘳𝘦 𝘤𝘳𝘶𝘤𝘪𝘢𝘭.

My work centres on helping biotech and pharmaceutical companies navigate the complexities of bringing innovative therapies to market. This includes strategic planning for funding, licensing, and M&A transactions, helping to create strategic partnerships.

Understanding the patent landscape is vital for strategic decision-making in ALS drug development. See my analysis of the ALS patent landscape.
 
Connect with me to explore how we can collaborate and drive meaningful progress.